US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

Scribe Therapeutics / Equity Capital Markets

<ul>
<li>Scribe priced above expectations, upsized its IPO, and opened 66.7% higher, highlighting exceptional institutional demand.</li>
<li>The deal wasmore than 10x oversubscribed, supported by strategic investments from Eli Lilly and Sanofi.</li>
<li>Although Phase 1 data is not expected until 2027, strong long-term holders should help preserve much of the IPO premium.</li>
</ul>


Scribe priced above expectations, upsized its IPO, and opened 66.7% higher, highlighting exceptional institutional demand.
The deal wasmore than 10x oversubscribed, supported by strategic investments from Eli Lilly and Sanofi.
Although Phase 1 data is not expected until 2027, strong long-term holders should help preserve much of the IPO premium.


Scribe Therapeutics (SCTX): Strong Hands, Strong Start: Scribe Therapeutics Impresses on Debut

<ul>
<li>Strategic backing includes a $7.5 million private placement from Sanofi affiliates and an anchor investment indication from Eli Lilly.</li>
<li>Scribe is developing next-generation CRISPR therapies targeting large cardiovascular markets, with initial Phase 1 data expected in 1H 2027.</li>
<li>Although early-stage and small in size, strong institutional sponsorship and industry validation support an optimistic view on the offering.</li>
</ul>


Strategic backing includes a $7.5 million private placement from Sanofi affiliates and an anchor investment indication from Eli Lilly.
Scribe is developing next-generation CRISPR therapies targeting large cardiovascular markets, with initial Phase 1 data expected in 1H 2027.
Although early-stage and small in size, strong institutional sponsorship and industry validation support an optimistic view on the offering.


Scribe Therapeutics Inc. (SCTX): CRISPR Biotech Attracts Blue-Chip Support, Demand Strong for IPO

Get Ahead with IPO Insights, IPO Prophet

IPO Prophet

Get Ahead with IPO Insights

At IPO Prophet®, our team leverages over three decades of expertise to deliver actionable quantitative analytics for the IPO market in real-time. This platform synthesizes our extensive experience investing in IPOs, providing investors with revolutionary tools to navigate the complexities of issuance day. Our mission is to empower investors with data-driven insights to make more informed decisions.

<ul><li>Scribe Therapeutics is expected to list on the Nasdaq under the ticker SCTX, offering approximately 7.15 million shares at a price range of $13.00 to $15.00 per share, targeting approximately $100 million in gross proceeds.</li><li>The company is developing next-generation CRISPR-based genetic medicines designed to improve the precision, specificity, and safety of gene editing therapies.</li><li>Its lead programs focus on cardiovascular and metabolic diseases, representing some of the largest potential markets within genomic medicine.</li></ul>

Scribe Therapeutics is expected to list on the Nasdaq under the ticker SCTX, offering approximately 7.15 million shares at a price range of $13.00 to $15.00 per share, targeting approximately $100 million in gross proceeds.The company is developing next-generation CRISPR-based genetic medicines designed to improve the precision, specificity, and safety of gene editing therapies.Its lead programs focus on cardiovascular and metabolic diseases, representing some of the largest potential markets within genomic medicine.

<ul><li>Scribe Therapeutics (NASDAQ: SCTX) has filed for an initial public offering of 7.15 million shares priced between $13.00 and $15.00 per share, targeting gross proceeds of approximately $100.1 million at the midpoint of the range.</li><li>At a midpoint price of $14.00, Scribe would debut with an implied market capitalization of approximately $226.5 million based on 16.18 million shares outstanding following the offering and concurrent private placement.</li><li>The IPO is being led by Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo Securities.</li></ul>

Scribe Therapeutics (NASDAQ: SCTX) has filed for an initial public offering of 7.15 million shares priced between $13.00 and $15.00 per share, targeting gross proceeds of approximately $100.1 million at the midpoint of the range.At a midpoint price of $14.00, Scribe would debut with an implied market capitalization of approximately $226.5 million based on 16.18 million shares outstanding following the offering and concurrent private placement.The IPO is being led by Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo Securities.

Scribe Therapeutics (SCTX) Targets $100 Million IPO

<ul>
<li>Scribe Therapeutics is set to revive biotech IPO activity with a CRISPR-focused offering backed by strategic investors Eli Lilly and Sanofi.</li>
<li>The clinical-stage biotech’s lead candidate, STX-1150, remains early with Phase 1 data expected in 1H27, requiring investor patience.</li>
<li>Scribe’s CRISPR platform targets large cardiovascular markets, supported by blue-chip partnerships and prominent venture investors including Andreessen Horowitz.</li>
</ul>


Scribe Therapeutics is set to revive biotech IPO activity with a CRISPR-focused offering backed by strategic investors Eli Lilly and Sanofi.
The clinical-stage biotech’s lead candidate, STX-1150, remains early with Phase 1 data expected in 1H27, requiring investor patience.
Scribe’s CRISPR platform targets large cardiovascular markets, supported by blue-chip partnerships and prominent venture investors including Andreessen Horowitz.


Scribe Therapeutics Inc. (SCTX): Small Cap CRISPR Biotech Sets Terms Seeking $100m Raise

United States

Scribe Therapeutics Inc. is a clinical-stage biotechnology company. The Company develops CRISPR-based genetic medicines for the treatment of cardiovascular and metabolic diseases. Scribe Therapeutics operates in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Scribe Therapeutics (SCTX US)

Scribe Therapeutics (SCTX): Strong Hands, Strong Start: Scribe Therapeutics Impresses on Debut

Scribe's successful IPO launch reflects strong institutional demand and strategic investments, with potential for long-term growth despite delayed...

IPO Boutique

Scribe Therapeutics Inc. (SCTX): CRISPR Biotech Attracts Blue-Chip Support, Demand Strong for IPO

Scribe secures $7.5 million in funding from Sanofi and Eli Lilly for developing CRISPR therapies for cardiovascular markets, with promising Phase...

IPO Boutique

IPO Rating: Scribe Therapeutics, Inc.

Scribe Therapeutics is expected to list on the Nasdaq under the ticker SCTX, offering approximately 7.15 million shares at a price range of $13.00...

IPO Prophet

Scribe Therapeutics (SCTX) Targets $100 Million IPO

Clinical-stage gene editing company looks to redefine cardiovascular care with proprietary CRISPR technologies designed for durable, scalable...

IPO Prophet

Scribe Therapeutics Inc. (SCTX): Small Cap CRISPR Biotech Sets Terms Seeking $100m Raise

Scribe Therapeutics poised to revitalize biotech IPOs with CRISPR-focused offering backed by strategic investors, targeting cardiovascular markets...

IPO Boutique

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Scribe Therapeutics (SCTX): Strong Hands, Strong Start: Scribe Therapeutics Impresses on Debut

​Scribe's successful IPO launch reflects strong institutional demand and strategic investments, with potential for long-term growth despite delayed...

IPO Boutique

Scribe Therapeutics Inc. (SCTX): CRISPR Biotech Attracts Blue-Chip Support, Demand Strong for IPO

​Scribe secures $7.5 million in funding from Sanofi and Eli Lilly for developing CRISPR therapies for cardiovascular markets, with promising Phase...

IPO Boutique

IPO Rating: Scribe Therapeutics, Inc.

Scribe Therapeutics is expected to list on the Nasdaq under the ticker SCTX, offering approximately 7.15 million shares at a price range of $13.00...

IPO Prophet

Scribe Therapeutics (SCTX) Targets $100 Million IPO

Clinical-stage gene editing company looks to redefine cardiovascular care with proprietary CRISPR technologies designed for durable, scalable...

IPO Prophet

Scribe Therapeutics Inc. (SCTX): Small Cap CRISPR Biotech Sets Terms Seeking $100m Raise

​Scribe Therapeutics poised to revitalize biotech IPOs with CRISPR-focused offering backed by strategic investors, targeting cardiovascular markets...

IPO Boutique

Scribe's successful IPO launch reflects strong institutional demand and strategic investments, with potential for long-term growth despite delayed...

Scribe secures $7.5 million in funding from Sanofi and Eli Lilly for developing CRISPR therapies for cardiovascular markets, with promising Phase...

Scribe Therapeutics poised to revitalize biotech IPOs with CRISPR-focused offering backed by strategic investors, targeting cardiovascular markets...